Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program.

Related Articles

Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program.

Antimicrob Agents Chemother. 2014 May;58(5):2921-4

Authors: Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN

Abstract
In this study, oritavancin had modal MIC, MIC50, and MIC90 values of 0.03, 0.03, and 0.06 μg/ml, respectively, against Staphylococcus aureus. Similar results (MIC50/90, 0.03/0.06 μg/ml) were observed against methicillin-resistant and -susceptible isolates and those demonstrating multidrug-resistant (MDR) and non-MDR phenotypes. When oritavancin (MIC50/90, 0.06/0.12 mg/ml) was tested against S. aureus with elevated MIC values for daptomycin (i.e., 1 to 4 mg/ml) and vancomycin (i.e., 2 mg/ml), it showed MIC results 2-fold higher than those for the more susceptible vancomycin or daptomycin counterparts (MIC50/90, 0.03/0.06 mg/ml), yet it inhibited these isolates at ≤0.25 mg/ml.

PMID: 24550323 [PubMed - indexed for MEDLINE]